Dermatologist Highlights Medical Benefits of MelaFind Device in Aiding Melanoma Diagnosis at Most Treatable Stage “This is the wave of the future for dermatology.” 10th Annual Maui Derm Conference Business Wire MAUI, Hawaii & IRVINGTON, N.Y. -- January 30, 2014 MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind^®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, hosted a MelaFind^® workshop during the 10^th Annual Maui Derm Conference in Hawaii. The conference seeks to increase physicians’ knowledge of developments in medical and cosmetic dermatology. Dr. Monica Scheel, a Board Certified Dermatologist based in Hawaii, hosted the MelaFind^® workshop which reviewed the clinical use and benefits of the device as well as future technology development opportunities for the device and its underlying optical imaging and data analysis technology. Dr. Scheel had also presented clinical data at MELA Sciences’ Clinical Advisory meeting at the Winter Clinical Dermatology Conference held a week earlier. “Adding MelaFind to my practice has helped mobilize patients and drive disease awareness; I’m thrilled with this new technology,” commented Dr. Scheel. “This is the wave of the future for dermatology, a new way to visualize and analyze atypical pigmented skin lesions below the skin surface. MelaFind has helped increase the sensitivity of my biopsies, as well as helped me prioritize lesions that can be monitored.” MELA Sciences also displayed four clinical posters at the well-attended and highly successful Maui Derm conference. The posters reviewed clinical data from practice and clinical settings that highlighted how MelaFind has helped dermatologists in the assessment of clinically ambiguous pigmented skin lesions (moles) in a variety of patient types including young adults, an area of growing concern, and those with atypical mole syndrome. The posters and abstracts are available here. About MELA Sciences, Inc. www.melasciences.com MELA Sciences is a medical device company developing dermatology diagnostics utilizing state-of-the-art optical imaging. The flagship product is MelaFind^®, an FDA, PMA and CE Mark approved, non-invasive diagnostic tool to aid dermatologists in melanoma evaluation and diagnosis. MelaFind^® uses a variety of visible to near-infrared light waves to evaluate skin lesions (moles) from the surface to 2.5 mm beneath the skin. It provides images and data on the relative disorganization of a lesion's structure that provides substantial additional perspective to aid melanoma diagnosis. MELA is also exploring new potential uses for its core imaging technology and algorithms. Twitter: MELASciencesIR or MelaFind Facebook: MelaFind StockTwits: MELASciencesIR Contact: Media MELA Sciences, Inc. Diana Garcia Redruello, 212-518-4226 firstname.lastname@example.org or Investors Catalyst Global Toni Trigiani, David Collins 212-924-9800 email@example.com
Dermatologist Highlights Medical Benefits of MelaFind Device in Aiding Melanoma Diagnosis at Most Treatable Stage
Press spacebar to pause and continue. Press esc to stop.